Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0600142 (
hot flushes
)
1,242
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The clinical and hormonal effects of long-term, continuous treatment with veralipride, a
benzamide
derivative, were investigated in 10 post-menopausal women. The efficacy of veralipride in relieving
hot flushes
was confirmed. No significant change was detected in depressive mood scores. Except for the late appearance of moderate extrapyramidal side effects in one patient, the clinical tolerance of veralipride was good. As regards hormonal effects, veralipride, by virtue of its antidopaminergic action, raised prolactin levels. Luteinizing hormone (LH) and follicle-stimulating hormone (FSH) levels declined significantly, while the serum concentration of dehydroepiandrosterone sulphate (DHEAS) increased. These hormonal changes were presumably secondary to the chronic hyperprolactinaemia.
...
PMID:Clinical and hormonal effects of long-term veralipride treatment in post-menopausal women. 318 94
21 women with menopausal disorders were given veralipride, which is a
benzamide
derivative having a central anti-dopaminergic action. The LH, FSH and PRL plasma levels were controlled before and after treatment. Treatment, using veralipride at a daily dose of 100 mg for 20 days, improved the climacteric syndrome, and, in particular, the sudden
hot flushes
. The FSH plasma levels remained unchanged, the LH levels were reduced, although they remained high, and the PRL levels increased during the course of the treatment.
...
PMID:[Effect of veralipride on LH, FSH, and PRL levels and on the climacteric syndrome]. 392 34
The perimenopausal period, from 1 to 4 years, is characterised by vasomotor symptoms, or
hot flushes
, and other effects due a deficit of estrogens. Approximately 85% of women have
hot flushes
for 1 year and 25 - 50% continue for up to 5 years. The cause of
hot flushes
has been linked to dysfunction of the thermoregulatory centre caused by estrogen withdrawal. One proposal for the aetiology of
hot flushes
is that the thermoregulatory zone is shifted downward in patients who experience
hot flushes
. Estrogen withdrawal creates a change of the central opioid system and a thermoregulatory instability. Estrogen and/or progestin replacement is the treatment of choice for this distressing symptom. However, steroid replacement may be associated with risks and complications, and is limited in some subjects by well-known contraindications. Veralipride, a synthetic
benzamide
derivative with antidopaminergic action, is effective in reducing the frequency and severity of
hot flushes
associated with menopausal hypoestrogenism, gaining interest as a non-hormonal treatment for climacteric flushing. In recent years, extrapyramidal disorders associated with veralipride therapy have been reported and are often due to drug misuse. Adverse effects include acute dyskinesia or Parkinsonism, which may occur after many months of treatment. An association between adverse effects and mistake of administration has been described. This article discusses available data on the benefits and risks of veralipride therapy for menopausal symptoms.
...
PMID:The safety of veralipride. 1690 59